Galvin, James E.
Article History
First Online: 26 January 2018
Compliance with Ethical Standards
:
: James Galvin is the primary copyright holder of the AD8 (with Washington University) and the QDRS (with New York University). His research is supported by grants from NIH (R01 AG040211, U01 NS100610, R01 AG054425, and R01 AG056610), the Florida Department of Health, and the Harry T. Mangurian Foundation. He serves as a consultant for Biogen, Axovant, Eli Lilly, and Eisai. He directs clinical trials for Novartis, Amgen, Genentech, Biogen, Janssen, and Axovant. None of the sponsors are involved in the development or publication of this manuscript.
: This article does not contain any studies with human or animal subjects performed by any of the authors.